Virpax Pharmaceuticals Inc

VRPX17 Jan 2025
Healthcare
$0.33
-0.10 (-10.08%)
Lowest Today
$0.31
Highest Today
$0.35
Today’s Open
$0.33
Prev. Close
$0.35
52 Week High
$5.48
52 Week Low
$0.29
To Invest in Virpax Pharmaceuticals Inc

Virpax Pharmaceuticals Inc

Healthcare
VRPX17 Jan 2025
-0.10 (-10.08%)
1M
3M
6M
1Y
5Y
Low
$0.3
Day’s Range
High
$0.34
0.3
52 Week Low
$0.29
52-Week Range
52 Week High
$5.48
0.29
1 Day
-
1 Week
-11.42%
1 month return
-8.01%
3 month return
-46.27%
6 month return
-78.91%
1 Year return
-88.51%
3 Years return
-98.94%
5 Years return
-
10 Years return
-
Institutional Holdings
Garden State Investment Advisory Services LLC
0.71
Citadel Advisors Llc
0.39
Geode Capital Management, LLC
0.35
UBS Group AG
0.25
Fidelity Extended Market Index
0.17
TWO SIGMA SECURITIES, LLC
0.15
Fidelity Total Market Index
0.06

Market Status

Fundamentals
Market Cap
3.03 mln
PB Ratio
0.48
PE Ratio
0
Enterprise Value
5.12 mln
Total Assets
9.63 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.
Organisation
Virpax Pharmaceuticals Inc
Employees
7
Industry
Biotechnology
CEO
Mr. Jatinder  Dhaliwal
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step